Fund Raising – Talk Bio

SanegeneBio raises over $110M Series B after Lilly RNAi deal

1 month ago talkbio0Tagged clinical-stage assets, eli lilly, extrahepatic RNAi, Fund Raising, Lilly collaboration, liver-targeted RNAi, Metabolic Diseases, RNA, RNA Interference, SanegeneBio, Series B financing

SanegeneBio; Series B financing; $110 million; Eli Lilly; RNA interference; RNAi therapeutics; metabolic diseases; Lilly collaboration; clinical-stage assets; liver-targeted RNAi; extrahepatic RNAi; biotech fundraising 2025

Major Leadership Changes and Fundraising in Biotech: Metagenomi CEO Exit, Workforce Cuts; Cogent Biosciences Raises Over $475M

2 months ago talkbio0Tagged bezuclastinib, Brian Thomas, CEO, Cogent Biosciences, Exit, Fund Raising, hemophilia A program, Irish (ethnic group), Jian, layoffs, Metagenomi, pipeline focus, Workforce

Metagenomi; CEO exit; Brian Thomas; Jian Irish; workforce cuts; biotech layoffs; Cogent Biosciences; fundraising; bezuclastinib; hemophilia A program; pipeline focus

Connecticut Biotech Veradermics Secures $150M for Phase 3 Trials of Oral Rogaine

3 months ago talkbio0Tagged Biotechnology, Clinical Development, Clinical Trials, Connecticut biotech, Fund Raising, hair loss treatment, Oral cavity, Phase 3, Rogaine, Veradermics

Veradermics; Connecticut biotech; oral Rogaine; Phase 3 clinical trials; fundraising; hair loss treatment; biotechnology; clinical development

Satellos Advances Duchenne Pill Trial in Children; Idorsia Raises $81 Million

3 months ago talkbio0Tagged Child, Fund Raising, Idorsia, Indonesian language, Muscular Dystrophy, Duchenne, oral small-molecule therapy, Phase 2 clinical trial, SAT-3247, Satellos, Submission, United States Food and Drug Administration

Satellos; Duchenne muscular dystrophy; SAT-3247; Phase 2 clinical trial; children; FDA IND submission; oral small-molecule therapy; Idorsia; fundraising; biotech